Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, Nanjing 210002, China.
Inflammation. 2012 Jun;35(3):871-80. doi: 10.1007/s10753-011-9388-3.
This study aims to determine whether levosimendan combined with arginine vasopressin infusion supplemented with norepinephrine can improve hemodynamics and pulmonary dysfunction. The study was tested in a fecal peritonitis-induced septic shock model, we observed that levosimendan combined with arginine vasopressin supplemented with norepinephrine therapy resulted in lower mean pulmonary artery pressure, lactate concentrations, arterial total nitrate/nitrite, and high-mobility group box 1 levels; decreased lung wet/dry ratio, and pulmonary levels of interleukin-6, total histological scores, and improved pulmonary gas exchange when compared with norepinephrine group. Levosimendan combined with arginine vasopressin supplemented with norepinephrine infusion shows potential benefit in sepsis-induced acute lung injury by decreasing mean pulmonary artery pressure and attenuating inflammatory responses in the lung compared to norepinephrine infusion alone.
本研究旨在确定左西孟旦联合血管加压素与去甲肾上腺素输注是否可以改善血流动力学和肺功能障碍。该研究在粪便腹膜炎诱导的感染性休克模型中进行，我们观察到左西孟旦联合血管加压素与去甲肾上腺素治疗可降低平均肺动脉压、乳酸浓度、动脉总硝酸盐/亚硝酸盐和高迁移率族蛋白 1 水平；与去甲肾上腺素组相比，肺湿/干比、肺组织学总评分和改善肺气体交换降低，白细胞介素-6、肺水平降低。与单纯去甲肾上腺素输注相比，左西孟旦联合血管加压素与去甲肾上腺素输注可降低平均肺动脉压，减轻肺内炎症反应，对感染性休克引起的急性肺损伤有潜在益处。
